The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Ramakanth Swayampakula - H.C. Wainwright & Co., LLC - Analyst
: Thank you. This is RK from H.C. Wainwright. Good morning, folks. A couple of quick questions from me. On the breast implant program, what's the
regulatory pathway and what additional studies do you need to do before getting on to the regulatory pathway?
Question: Ramakanth Swayampakula - H.C. Wainwright & Co., LLC - Analyst
: Thank you for that. So when do you think you can start the PMA process? Or can you start it as you're getting through your next animal study?
Question: Ramakanth Swayampakula - H.C. Wainwright & Co., LLC - Analyst
: Okay. Thanks for that. And then on the gut-on-a-chip program, how do you plan to monetize this? Is this going to be a transaction for the platform
itself? Or do you think either you or you along with a collaborator can be providing this as a service to the drug developer market?
Question: Ramakanth Swayampakula - H.C. Wainwright & Co., LLC - Analyst
: Okay, thanks. Thanks for taking my questions.
Question: Steve Perry - Perco Industries - Analyst
: First of all, thank you for taking me in. Great quarter you guys just came in with. My questions are around timing. Just wondering, for the dermal
filler market, when does the actual study begin, and what's the timing and length of that study that it's going to take to commercialize that product,
if you have any idea? What's your thoughts on that?
Question: Steve Perry - Perco Industries - Analyst
: No, it is. And so quick question on size of the market as far as dermal fillers go. I've read some different numbers that the worldwide size of the
dermal filler market is about $5.5 billion. But I've also read that that can go as high as $9 billion or $10 billion. Where do you think the size of that
market is?
Question: Steve Perry - Perco Industries - Analyst
: Got it. Okay. All right. Those were my questions.
Question: Steve Perry - Perco Industries - Analyst
: And I don't know if you can disclose this or not, in retrospect to Allergan and the JUV+DERM market, this product gets approved, does it become
100% accepted and used exclusively by Allergan, replacing its current dermal filler? Or is it going to be in combination and offering both different
products?
Question: Steve Perry - Perco Industries - Analyst
: Okay. All right. Well, I appreciate your time, guys. Thank you so much.
Question: Ben Haynor - Alliance Global Partners - Analyst
: Good morning, gentlemen. Thanks for taking the questions, and congrats on the milestone payment from AbbVie. First off for me, I know with
AbbVie there was an upfront clinical regulatory commercial milestones associated with it. Are there more clinical milestones or is regulatory the
next one that we should be looking at?
Question: Ben Haynor - Alliance Global Partners - Analyst
: Okay. So you can't share whether the next one might be of a certain type?
Question: Ben Haynor - Alliance Global Partners - Analyst
: Okay, that's fair enough. I understand. And then just secondly for me on the cross-promotion that you guys have with Stratasys, any initial returns
so far? How has that been going, expectations there? Just curious on the bioink side of things and the relationship with Stratasys.
Question: Ben Haynor - Alliance Global Partners - Analyst
: Sure. I was just wondering on the cross-promotion that you guys are doing with Stratasys, if there have been any, I guess maybe not initial successes
there, but how are those conversations going? Any expectations on what that could lead to down the road with Stratasys?
Question: Ben Haynor - Alliance Global Partners - Analyst
: Okay. So that's still a little ways off.
Question: Ben Haynor - Alliance Global Partners - Analyst
: Okay, understood. Excellent. Well, thanks for taking the questions, gentlemen. And again, congrats on the AbbVie milestone.
| 
